IKVAVC 

IKVAVC is a derivative peptide of IKVAV with an artificially added cysteine (Cys) at its C-terminus. IKVAVC retains all the biological activities of the original IKVAV, mainly acting as a neural adhesion/differentiation signaling peptide, and is equipped with an engineered linker arm that enables covalent conjugation to molecular materials. IKVAV inhibits the migration and activation of fibroblasts, downregulates the TGF-β1 signaling pathway and endoplasmic reticulum stress, and promotes nerve repair. IKVAV regulates the phenotype of macrophages, shifting them from the pro-inflammatory M1 type to the pro-reparative M2 type^[1][2][3].

IKVAVC is covalently conjugated to biomaterials such as hydrogels and dendrimers via chemical reactions. This functionalized material can provide bioactive signals in a long-term, stable manner, construct a bionic microenvironment conducive to nerve regeneration and angiogenesis, and shows application potential in the treatment of diseases such as spinal cord injury^[1][2][3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

631.83

C₂₈H₅₃N₇O₇S

1187540-64-2

Ile-Lys-Val-Ala-Val-Cys

IKVAVC

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Yin Y, et al. Pentapeptide IKVAV-engineered hydrogels for neural stem cell attachment. Biomater Sci. 2021;9(8):2887-2892.

  [2]. Jiang T, et al. IKVAV peptide-containing hydrogel decreases fibrous scar after spinal cord injury by inhibiting fibroblast migration and activation. Behav Brain Res. 2023;455:114683.

  [3]. Jha A, et al. Laminin-derived peptide, IKVAV, modulates macrophage phenotype through integrin mediation. Matrix Biol Plus. 2024;22:100143. Published 2024 Feb 15.